Axonics Modulation Technologies (NASDAQ:AXNX) and Scivanta Medical (OTCMKTS:SCVM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
This is a breakdown of recent recommendations for Axonics Modulation Technologies and Scivanta Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axonics Modulation Technologies||0||0||8||0||3.00|
Axonics Modulation Technologies currently has a consensus price target of $42.50, suggesting a potential upside of 64.60%. Given Axonics Modulation Technologies’ higher possible upside, equities research analysts clearly believe Axonics Modulation Technologies is more favorable than Scivanta Medical.
Earnings and Valuation
This table compares Axonics Modulation Technologies and Scivanta Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Axonics Modulation Technologies||$710,000.00||1,040.18||-$32.48 million||($4.64)||-5.56|
Scivanta Medical has lower revenue, but higher earnings than Axonics Modulation Technologies.
Insider & Institutional Ownership
34.0% of Axonics Modulation Technologies shares are owned by institutional investors. 36.0% of Axonics Modulation Technologies shares are owned by company insiders. Comparatively, 34.0% of Scivanta Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Axonics Modulation Technologies has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500. Comparatively, Scivanta Medical has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
This table compares Axonics Modulation Technologies and Scivanta Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axonics Modulation Technologies||-1,530.43%||-55.57%||-44.28%|
Axonics Modulation Technologies beats Scivanta Medical on 5 of the 9 factors compared between the two stocks.
About Axonics Modulation Technologies
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
About Scivanta Medical
Scivanta Medical Corporation does not have significant operations. Previously, it was engaged in the development, manufacture, and distribution of the Scivanta cardiac monitoring system. The company intends to acquire a new technology, product, or service. The company was formerly known as Medi-Hut Co., Inc. The company was founded in 1981 and is headquartered in Spring Lake, New Jersey.
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.